Ameriprise Financial Inc. raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,476 shares of the company's stock after purchasing an additional 23,727 shares during the period. Ameriprise Financial Inc. owned about 0.39% of Krystal Biotech worth $17,779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of KRYS. Covestor Ltd raised its position in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares in the last quarter. Avanza Fonder AB acquired a new stake in Krystal Biotech in the 4th quarter valued at about $119,000. KBC Group NV raised its position in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. raised its position in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its position in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
A number of research firms have recently commented on KRYS. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Citigroup dropped their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital reiterated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Finally, Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $211.13.
Get Our Latest Stock Report on Krystal Biotech
Krystal Biotech Stock Down 1.1%
KRYS traded down $1.39 during trading on Thursday, hitting $125.29. 470,248 shares of the stock were exchanged, compared to its average volume of 307,433. The firm has a market capitalization of $3.62 billion, a P/E ratio of 41.90 and a beta of 0.79. Krystal Biotech, Inc. has a 1-year low of $125.02 and a 1-year high of $219.34. The stock has a fifty day moving average price of $162.61 and a two-hundred day moving average price of $167.37.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
